TAKARA BIO (4974) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The most important point in these results is that, despite the relatively small decline in revenue, profitability deteriorated significantly due to a decline in the gross profit margin and an increase in SG&A expenses. Revenue was ¥283.9B (-3.0% YoY), Operating Income was ¥-48.5B (deteriorating from ¥-14.7B in the previous year), Ordinary Income was ¥-50.9B (deteriorating from ¥-12.6B in the previous year), and Net Income was ¥-95.9B (deteriorating from ¥-13.5B in the previous year). The gross profit margin declined to 49.8% from 55.9% in the previous year, while the SG&A ratio rose to 66.9%. In addition, extraordinary losses of ¥39.7B, including an impairment loss of ¥38.7B, amplified the net loss.

Factors Affecting Business Performance

【Revenue】Revenue was ¥283.9B, down 3.0% YoY. Although a breakdown by business is not disclosed because the Company has a single segment, progress against the full-year company forecast of ¥421.0B was 67.4%, below the standard Q3 progress benchmark of approximately 75%.

【Profitability】In addition to the decline in revenue, the gross profit margin fell from 55.9% to 49.8%, while the SG&A ratio rose from 60.9% to 66.9%. As a result, the Operating Income margin deteriorated from -5.0% to -17.1%. Ordinary Income was ¥-50.9B, after the addition of ¥4.2B in interest expense as a non-operating expense. Extraordinary losses of ¥39.7B, mainly comprising an impairment loss of ¥38.7B, further expanded the Net Loss to ¥95.9B. Even excluding the impairment loss, an Operating Loss and Ordinary Loss remain; therefore, this represents a structural decline in revenue and earnings that cannot be explained solely by temporary factors.

Key Financial Indicators

【Profitability】The Operating Income margin deteriorated significantly to -17.1% (-5.0% in the previous year), while the Net Income margin deteriorated to -33.9% (-4.6% in the previous year). R&D expenses were ¥50.9B, maintaining a high level at 17.9% of revenue.【Cash Flow Quality】Operating Cash Flow (OCF) was positive at ¥32.6B, but the primary factor was a ¥57.5B cash inflow resulting from a decrease in accounts receivable, in contrast to the Net Loss of ¥95.9B. It is important to note that OCF being significantly better than Net Loss reflects temporary cash generation from working capital recovery.【Investment Efficiency】Annualized ROE was -12.6%. With total assets of ¥1,304.8B and revenue of ¥283.9B, asset turnover was low, indicating that capital expenditures and acquisition investments have not yet translated into revenue.【Financial Soundness】The Equity Ratio remained high at 77.7%, but net assets declined from ¥1,158.5B in the previous year to ¥1,013.3B. Although the Company has ¥100.0B in long-term borrowings, its ability to cover interest expenses has declined because Operating Income is negative.

Cash Flow Analysis

OCF was positive at ¥32.6B, but decreased 33.1% from ¥48.8B in the same period of the previous year. This OCF was in contrast to the Net Loss of ¥95.9B, with the primary factor being a ¥57.5B cash inflow from a decrease in accounts receivable. Inventories increased by ¥6.2B, reducing OCF. Investing Cash Flow was ¥-187.1B, mainly comprising ¥123.3B for the acquisition of property, plant and equipment and intangible assets and ¥64.2B for the acquisition of shares in subsidiaries. Financing Cash Flow was positive at ¥61.9B, with ¥99.5B raised through long-term borrowings covering part of the investment funding requirement. As a result, Free Cash Flow was ¥-154.4B, indicating that OCF was insufficient to fund investment expenditures. Cash and deposits were ¥198.3B, down 32.9% YoY, reflecting the consumption of funds during the period of expanded investment.

Earnings Quality

Of the ¥95.9B Net Loss, the ¥38.7B impairment loss was a temporary factor accounting for the majority of extraordinary losses. Even excluding this impairment loss, an Operating Loss of ¥48.5B and an Ordinary Loss of ¥50.9B remain. Accordingly, the deterioration in profitability cannot be explained solely by one-time items, and the primary cause is a decline in the profitability of the core business. Non-operating income was small at ¥3.1B, including ¥0.3B in foreign exchange gains, and was not sufficient to supplement the core business. Meanwhile, non-operating expenses of ¥5.5B, including ¥4.2B in interest expense, further depressed Ordinary Income. OCF of ¥32.6B moved in the opposite direction from Net Loss, with this divergence primarily attributable to the temporary collection of ¥57.5B resulting from a decrease in accounts receivable. Therefore, it is difficult to conclude that positive OCF indicates sustainable earnings-generating capacity, and the Company’s cash-generation ability excluding working capital effects will need to be monitored going forward.

Earnings Forecasts and Guidance

Against the full-year company forecasts (Revenue of ¥421.0B, Operating Income of ¥-40.0B, Ordinary Income of ¥-44.0B, and Net Income of ¥-90.0B), cumulative revenue progress was 67.4%, below the standard Q3 progress benchmark. Meanwhile, the cumulative Operating Loss of ¥48.5B had already exceeded the full-year forecast loss of ¥40.0B. The cumulative Ordinary Loss of ¥50.9B also exceeded the full-year forecast of ¥44.0B, while the cumulative Net Loss of ¥96.2B exceeded the full-year forecast of ¥90.0B. As of the current quarter, no revisions had been made to the earnings or dividend forecasts, and the plan premised on a significant improvement in profitability during Q4 remains in place.

Shareholder Returns

The Q2 dividend was ¥0, and the full-year dividend forecast is also ¥0. Because no dividend is planned, the Payout Ratio is not calculated. The ¥20.5B dividend payment shown in the statement of cash flows does not relate to the current period and represents a cash outflow associated with another period; it should therefore be treated separately. Given the Net Loss of ¥95.9B and Free Cash Flow of ¥-154.4B, the current no-dividend policy is consistent with a capital allocation policy that prioritizes R&D, capital expenditures, and acquisition investments.

Risk Factors

1. Structural deterioration in profitability: While revenue declined 3.0% YoY, the gross profit margin decreased by 610bp and the SG&A ratio increased by 600bp. If the recovery in revenue is delayed, the Company may be unable to absorb fixed costs, creating a risk that the Operating Loss will persist over an extended period.

2. Impairment risk related to goodwill and intangible assets: The Company recorded an impairment loss of ¥38.7B during the current period, while ¥120.6B in goodwill and ¥240.0B in intangible fixed assets remain on the balance sheet. If the acquired businesses generate earnings below plan, additional impairment losses may arise.

3. Dependence on cash flow and external financing: Free Cash Flow was ¥-154.4B, and the Company was unable to cover Investing Cash Flow of ¥187.1B with OCF of ¥32.6B. Continued dependence on ¥99.5B in funding raised through long-term borrowings could increase sensitivity to financing conditions.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Company’s profitability indicators were significantly below the industry median, with both its Operating Income margin and Net Income margin ranking low within the industry.

Growth and Capital Efficiency

The Company’s revenue growth rate was also below the industry median, positioning it as a company experiencing a decline in revenue within the industry.

※Source: Compiled by the Company

Key Points in the Financial Results

1. While the decline in revenue was limited to 3.0%, the combination of a lower gross profit margin and higher SG&A expenses caused the Operating Income margin to deteriorate significantly to -17.1%. Because an Operating Loss remains even excluding the impairment loss, the deterioration in profitability cannot be explained solely by temporary factors.

2. Construction in progress reached ¥270.5B, equivalent to 43.3% of property, plant and equipment, while intangible fixed assets and goodwill also increased significantly from the previous year. The timing of when these investment assets will become operational and generate revenue will be a key consideration in assessing improvements in capital efficiency.

3. As of the cumulative period, both the Operating Loss and Net Loss had already exceeded the full-year company forecasts. Since no forecast revisions have been made, the extent to which profitability improves during Q4 will be a focus of future earnings disclosures.

Theoretical Share Price (Reference Value)

Sensitivity: ¥468–¥494 at ±1% for the cost of equity, and ¥471–¥487 at ±0.1 for ω.

Notes:

• Goodwill amortization of ¥8.7 per share is added back to earnings (for non-cash expense treatment and comparability with IFRS companies).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---